{
    "clinical_study": {
        "@rank": "141066", 
        "arm_group": {
            "arm_group_label": "Fentanyl matrix"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix\n      in chronic non-cancer pain."
        }, 
        "brief_title": "The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Pain", 
        "detailed_description": {
            "textblock": "This is a multicenter, prospective (a study in which the patients are identified and then\n      followed forward in time for the outcome of the study), open-label (all people know the\n      identity of the intervention), observational study intended to examine the effectiveness of\n      Fentanyl matrix through the degree of improvement of pain. Fentanyl matrix is a transdermal\n      (through the skin) system providing continuous delivery of fentanyl for 72 hours. Fentanyl\n      matrix will be administered to patients with chronic (prolonged) non-cancer pain under\n      routine practice during 12 weeks. Dose will be adjusted in accordance with patient's degree\n      of pain and treatment response in the investigator's judgment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Complain of chronic non-cancer pain that persists for >= 3 months\n\n          -  Pain inadequately controlled by previous treatment with narcotic analgesics (opium or\n             opium-like compounds with potent analgesic effects, eg, tramadol, codeine, morphine,\n             oxycodone)\n\n          -  Women must be postmenopausal, surgically sterile, abstinent, or practicing an\n             effective method of birth control if they have childbearing potential\n\n          -  Male patients who agree to use a method of birth control and not to donate sperm for\n             1 month after the last dose of the study drug\n\n          -  A written informed consent for study participation\n\n        Exclusion Criteria:\n\n          -  Experience of treatment with Fentanyl matrix within the past 4 weeks\n\n          -  No previous experience of use of narcotic analgesics\n\n          -  Past or current history of alcohol or drug abuse\n\n          -  Cannot use transdermal analgesics due to skin disorder\n\n          -  Have serious psychiatric disorder and cannot complete overall study procedures and\n             questionnaire in the judgment of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who complain of chronic pain and have pain inadequately controlled by previous\n        treatment with narcotic analgesics (eg, tramadols, codeines, morphines, oxycodone), and\n        are judged to require Fentanyl matrix administration will participate in this study."
            }
        }, 
        "enrollment": {
            "#text": "410", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688583", 
            "org_study_id": "CR100728", 
            "secondary_id": [
                "FENPAI4094", 
                "FEN-KOR-5045"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Fentanyl matrix", 
            "description": "Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.", 
            "intervention_name": "Fentanyl matrix", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fentanyl"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic pain", 
            "Chronic non-cancer pain", 
            "Fentanyl matrix", 
            "Transdermal system"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Andong", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju-Si", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kwangiu", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kwanju", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wonju-Si", 
                        "country": "Korea, Republic of"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Republic of Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).", 
            "measure": "The percentage of patients with mean % Pain Intensity Difference (%PID) >= 50% from baseline to endpoint", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain intensity will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).", 
                "measure": "The change from baseline in mean pain intensity", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "The degree of pain the patient wishes to achieve by the end of treatment, set at baseline. The degree of pain will be measured using a numeric rating scale (NRS), from 0 (no pain) to 10 (worst pain imaginable).", 
                "measure": "The difference between the patient's pain treatment goal set at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Sleep disturbance due to pain will be measured using a Numeric Rating Scale (NRS): 1 = None, 10 = Complete.", 
                "measure": "The degree of night sleep disturbance due to pain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The degree of interference with daily life performance due to pain will be assessed on a 5-point scale: 1 = No interference, 5 = Great interference. Daily life performance means household work performance, etc.", 
                "measure": "The degree of Interference with Daily Life Performance due to Pain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The degree of interference with social life performance due to pain will be measured on a 5-point scale; 1 = No interference, 5 = Great interference. Social life performance means interpersonal relationship, going out, working life, etc.", 
                "measure": "The degree of Interference with Social Life Performance due to Pain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The patient will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been in the judgment of the study participant.", 
                "measure": "The patient's global assessment of pain treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The investigator will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been for a patient, in the judgment of the investigator.", 
                "measure": "The investigator's global assessment of pain treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}